For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
July 8, 2002
- CORPORATE ROUNDUP NEWS IN BRIEF
July 8, 2002
- Ain Pharmaciez: Sales Up 26.1% to \24.7 Bil.
July 8, 2002
- Korosho to Convert OPSR into Independent Administrative Agency in April 2004
July 8, 2002
- Tsuruha Acquires Potato Company of Yamagata
July 8, 2002
- Korosho Quickly Reviews NDA for Useful Drugs
July 8, 2002
- Discussions on Role of OTC Drugs Begin: Korosho
July 8, 2002
- ADRs Likely Caused by Glivec Reported: Korosho
July 8, 2002
- Pharmacists Ranked 5th in FY2002 Honesty/Ethics in Profession Poll
July 8, 2002
- Revised Bill of Health Insurance Law Approved by Lower House
July 8, 2002
- Iwaki Launches Mechanical Ventilators
July 8, 2002
- 1st-Class Products Invite 1st-Class People:Dr Aoki of Fujisawa
July 8, 2002
- REGULATORY NEWS IN BRIEF
July 8, 2002
- Korosho Compiles Report on Healthcare Devices
July 8, 2002
- BULLETIN
July 8, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
July 8, 2002
- PRESS SEMINAR
July 8, 2002
- Novartis Aims at \70 Bil. Sales of Diovan in 2004
July 8, 2002
- Candesartan Reduces Risk of Non-fatal Stroke in the Elderly
July 8, 2002
- Wako Pure Chemical Starts Contract DNA Sequencing Services
July 8, 2002
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…